GO
Loading...

Eli Lilly and Co

More

  • Final Glance: Pharmaceuticals companies Monday, 14 Apr 2014 | 6:01 PM ET

    Baxter International Inc. rose$. 78 or 1.1 percent, to $72.76. Bristol-Myers Squibb Co. fell$. 87 or 1.8 percent, to $47.96. Hospira rose$. 79 or 1.9 percent, to $42.93.

  • Midday Glance: Pharmaceuticals companies Monday, 14 Apr 2014 | 2:08 PM ET

    Baxter International Inc. rose$. 79 or 1.1 percent, to $72.77. Bristol-Myers Squibb Co. fell$. 39 or. 8 percent, to $48.44. Hospira rose $1.35 or 3.2 percent, to $43.49.

  • Early Glance: Pharmaceuticals companies Monday, 14 Apr 2014 | 10:21 AM ET

    Baxter International Inc. rose$. 47 or. 7 percent, to $72.45. Bristol-Myers Squibb Co. fell$. 07 or. 1 percent, to $48.77. Hospira rose$. 10 or. 2 percent, to $42.24.

  • Final Glance: Pharmaceuticals companies Friday, 11 Apr 2014 | 6:03 PM ET

    Baxter International Inc. fell$. 28 or. 4 percent, to $71.98. Bristol-Myers Squibb Co. fell$. 46 or. 9 percent, to $48.83. Hospira fell$. 58 or 1.4 percent, to $42.14.

  • Midday Glance: Pharmaceuticals companies Friday, 11 Apr 2014 | 1:51 PM ET

    Baxter International Inc. rose$. 15 or. 2 percent, to $72.41. Bristol-Myers Squibb Co. rose$. 07 or. 1 percent, to $49.36. Hospira fell$. 26 or. 6 percent, to $42.46.

  • Early Glance: Pharmaceuticals companies Thursday, 10 Apr 2014 | 10:24 AM ET

    Baxter International Inc. fell$. 37 or. 5 percent, to $73.08. Bristol-Myers Squibb Co. fell$. 45 or. 9 percent, to $50.12. Hospira fell$. 56 or 1.3 percent, to $43.65.

  • Final Glance: Pharmaceuticals companies Wednesday, 9 Apr 2014 | 6:06 PM ET

    Baxter International Inc. rose $1.15 or 1.6 percent, to $73.45. Bristol-Myers Squibb Co. rose $1.51 or 3.1 percent, to $50.57. Hospira rose$. 69 or 1.6 percent, to $44.21.

  • Midday Glance: Pharmaceuticals companies Wednesday, 9 Apr 2014 | 1:15 PM ET

    Baxter International Inc. rose$. 62 or. 9 percent, to $72.92. Bristol-Myers Squibb Co. rose$. 87 or 1.8 percent, to $49.93. Hospira rose$. 52 or 1.2 percent, to $44.04.

  • *Louisiana jury orders $6 bln damages from Takeda, $3 bln from Eli Lilly. *Award unlikely to stand after Takeda and Eli Lilly challenges. Eli Lilly and Co, Takeda's co-defendant in the case, was ordered to pay $3 billion in punitive damages by the jury in Louisiana on Monday.

  • *Amazon.com, Yahoo shares up 3 pct on Internet rebound. *Earnings get under way; Alcoa to report after bell. The day's biggest gainers included Amazon.com Inc up 2.3 percent at $324.99, Yahoo!

  • April 8- Alkermes Plc said it planned to seek U.S. marketing approval for its experimental drug to treat the symptoms of schizophrenia after it succeeded in a late-stage study, sending the company's shares up as much as 11 percent. The growing market for atypical antipsychotics for schizophrenia was worth $4.5 billion in the United States, Pops said.

  • Early Glance: Pharmaceuticals companies Tuesday, 8 Apr 2014 | 10:43 AM ET

    Baxter International Inc. rose$. 24 or. 3 percent, to $72.73. Johnson& Johnson rose$. 04 or percent, to $97.93. Eli Lilly& Co. rose$. 04 or. 1 percent, to $58.66.

  • *Eli Lilly ordered to pay $3 bln in damages in Actos case. *Alcoa earnings due after the close.

  • Stocks drift after a three-day slump; Lilly falls Tuesday, 8 Apr 2014 | 9:49 AM ET

    NEW YORK— Stocks are drifting mostly higher in early trading on Wall Street as the market stabilizes after a three-day slump. Aluminum maker Alcoa reports earnings after the close of trading Tuesday.

  • US stocks rise for the first time in four days Tuesday, 8 Apr 2014 | 9:20 AM ET

    NEW YORK— Maybe the sell-off was a little overdone. That was the sentiment on Wall Street Tuesday as the stock market broke a three-day losing streak. "Longer-term investors should really use this as an opportunity to buy attractive areas that have sold off," said Kristina Hooper, US Investment Strategist at Allianz Global Investors.

  • *Eli Lilly ordered to pay $3 bln in damages in Actos case. *Alcoa earnings due after the close. *Earnings season gets under way this week, with results due from companies including Alcoa Inc after the close, retailer Bed, Bath& Beyond on Wednesday, while financials JPMorgan Chase& Co and Wells Fargo& Co close out the week with results on Friday.

  • April 8- Alkermes Plc said its experimental drug to treat the symptoms of schizophrenia met the main goal of reducing the severity of symptoms of the disease in a late-stage study. Alkermes success comes about a week after Australia- based Prana Biotechnology said its experimental drug to treat Alzheimer's disease failed a mid-stage study.

  • *Eli Lilly ordered to pay $3 bln in damages in Actos case. *Alcoa earnings due after the close. *Earnings season gets under way this week, with results due from companies including Alcoa Inc after the close, retailer Bed, Bath& Beyond on Wednesday, while financials JPMorgan Chase& Co and Wells Fargo& Co close out the week with results on Friday.

  • *Louisiana jury orders $6 bln damages from Takeda, $3 bln from Eli Lilly. SAN FRANCISCO/ TOKYO, April 8- Takeda Pharmaceutical Co Ltd said it would contest $6 billion in punitive damages imposed by a U.S. federal jury in a case alleging that Japan's largest drugmaker had concealed cancer risks associated with its Actos diabetes drug.

  • US jury hits Takeda, Eli Lilly with $9B penalty Tuesday, 8 Apr 2014 | 3:33 AM ET

    TOKYO— A U.S. jury ordered Japanese drugmaker Takeda Pharmaceutical Co. and its U.S. counterpart, Eli Lilly and Co., to pay $9 billion in punitive damages over a diabetes medicine linked to cancer. The U. S District Court in western Louisiana ordered a $6 billion penalty for Takeda and $3 billion for its business partner and co-defendant Eli Lilly.

Most Popular Video

Wednesday, 16 Apr 2014 | 3:00 AM ET

European shares opened higher on Wednesday as better-than-expected Chinese growth data buoyed sentiment.

Wednesday, 16 Apr 2014 | 2:00 AM ET

Brady Dougan, CEO of Credit Suisse, says the bank's fixed income business is "strong", while the investment banking arm has performed well.

Tuesday, 15 Apr 2014 | 7:31 PM ET

Hiroshi Miyoshi, Mitsubishi CEO for Turkey and Central Asia, describes Turkey's appeal to Japanese firms, who invested $500 million in the emerging market last year.